Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811184474> ?p ?o ?g. }
- W2811184474 endingPage "e180349" @default.
- W2811184474 startingPage "e180349" @default.
- W2811184474 abstract "<h3>Importance</h3> As survival rates from cancer have improved dramatically over the last decades, there is a need to explore the long-term consequences. Adolescents and young adults with cancer are at risk for several therapy-related late effects; however, these have not been studied extensively. <h3>Objective</h3> To investigate the lifetime risks of endocrine late effects of cancer and cancer treatment in adolescent and young adult cancer survivors. <h3>Design, Setting, and Participants</h3> This Danish, nationwide, population-based cohort study was conducted from January 1, 1976, through December 31, 2009, and included follow-up from January 1, 1977, through December 31, 2010. A total of 32 548 one-year cancer survivors diagnosed at ages 15 to 39 years were identified using the Danish Cancer Registry and 188 728 cancer-free comparison participants matched by year of birth and sex were randomly chosen from the Danish Civil Registration system. Analyses were performed from July 3, 2015, to February 27, 2018. <h3>Exposures</h3> Individuals in the survivor cohort were diagnosed with a first primary cancer at ages 15 to 39 years and received treatment according to recommendations and guidelines at time of diagnosis. <h3>Main Outcomes and Measures</h3> By linkage to the National Patient Register, all hospital contacts for endocrine diseases were identified, and standardized hospitalization rate ratios (RRs) and absolute excess risks (AERs) were calculated. <h3>Results</h3> A total of 32 548 adolescent and young adult 1-year cancer survivors (14 021 [43.1%] male) in the Danish Patient Registry were followed up for 379 157 person-years (median [range]: 10 [0-34] years) and 188 728 cancer-free participants (82 669 [43.8%] male) for comparison were followed up for 2 958 994 person-years (median [range]: 15 [0-34] years). A total of 2129 survivors (6.5%) had at least 1 hospital contact for an endocrine disease, while 1232.0 (3.8%) were expected, yielding a statistically significant increased RR of 1.73 (95% CI, 1.65-1.81). The RRs were highest for testicular hypofunction (75.12; 95% CI, 45.99-122.70), ovarian hypofunction (14.65; 95% CI, 8.29-25.86), and pituitary hypofunction (11.14; 95% CI, 8.09-15.34). The leading reasons for hospital contacts were thyroid disease (38.0% of total AER), testicular dysfunction (17.1% of total AER), and diabetes (14.4% of total AER). Leukemia survivors were at a high risk for any endocrine disease (RR, 3.97; 95% CI, 3.10-5.09), while Hodgkin lymphoma survivors (RR, 3.06; 95% CI, 2.62-3.57) had the highest disease-specific excess risk for hypothyroidism (AER, 362 per 100 000 person-years; 95% CI, 280-443 per 100 000 person-years). <h3>Conclusions and Relevance</h3> The increased risk for endocrine diseases in adolescent and young adult cancer survivors indicates the need for counseling and follow-up, and could guide future preventive measures and surveillance strategies. Additional studies are required to determine exact associations between treatment regimens and endocrine diseases." @default.
- W2811184474 created "2018-07-10" @default.
- W2811184474 creator A5023221857 @default.
- W2811184474 creator A5037521446 @default.
- W2811184474 creator A5044190214 @default.
- W2811184474 creator A5059586220 @default.
- W2811184474 creator A5069619584 @default.
- W2811184474 creator A5074845542 @default.
- W2811184474 creator A5084307288 @default.
- W2811184474 date "2018-06-29" @default.
- W2811184474 modified "2023-10-18" @default.
- W2811184474 title "Endocrine Late Effects in Survivors of Cancer in Adolescence and Young Adulthood" @default.
- W2811184474 cites W1548499810 @default.
- W2811184474 cites W1602856335 @default.
- W2811184474 cites W1849451034 @default.
- W2811184474 cites W1913985783 @default.
- W2811184474 cites W1978670003 @default.
- W2811184474 cites W1986987266 @default.
- W2811184474 cites W1991401391 @default.
- W2811184474 cites W2015758016 @default.
- W2811184474 cites W2031508694 @default.
- W2811184474 cites W2044934343 @default.
- W2811184474 cites W2057186731 @default.
- W2811184474 cites W2067799640 @default.
- W2811184474 cites W2077788260 @default.
- W2811184474 cites W2088188667 @default.
- W2811184474 cites W2096395073 @default.
- W2811184474 cites W2102420102 @default.
- W2811184474 cites W2102924526 @default.
- W2811184474 cites W2110873582 @default.
- W2811184474 cites W2135214270 @default.
- W2811184474 cites W2145908651 @default.
- W2811184474 cites W2147662523 @default.
- W2811184474 cites W2160208506 @default.
- W2811184474 cites W2163019124 @default.
- W2811184474 cites W2175566334 @default.
- W2811184474 cites W2324624347 @default.
- W2811184474 cites W2332327722 @default.
- W2811184474 cites W2338359569 @default.
- W2811184474 cites W2432458834 @default.
- W2811184474 cites W4255698410 @default.
- W2811184474 doi "https://doi.org/10.1001/jamanetworkopen.2018.0349" @default.
- W2811184474 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324403" @default.
- W2811184474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646084" @default.
- W2811184474 hasPublicationYear "2018" @default.
- W2811184474 type Work @default.
- W2811184474 sameAs 2811184474 @default.
- W2811184474 citedByCount "32" @default.
- W2811184474 countsByYear W28111844742018 @default.
- W2811184474 countsByYear W28111844742019 @default.
- W2811184474 countsByYear W28111844742020 @default.
- W2811184474 countsByYear W28111844742021 @default.
- W2811184474 countsByYear W28111844742022 @default.
- W2811184474 countsByYear W28111844742023 @default.
- W2811184474 crossrefType "journal-article" @default.
- W2811184474 hasAuthorship W2811184474A5023221857 @default.
- W2811184474 hasAuthorship W2811184474A5037521446 @default.
- W2811184474 hasAuthorship W2811184474A5044190214 @default.
- W2811184474 hasAuthorship W2811184474A5059586220 @default.
- W2811184474 hasAuthorship W2811184474A5069619584 @default.
- W2811184474 hasAuthorship W2811184474A5074845542 @default.
- W2811184474 hasAuthorship W2811184474A5084307288 @default.
- W2811184474 hasBestOaLocation W28111844741 @default.
- W2811184474 hasConcept C121608353 @default.
- W2811184474 hasConcept C126322002 @default.
- W2811184474 hasConcept C138885662 @default.
- W2811184474 hasConcept C144024400 @default.
- W2811184474 hasConcept C149923435 @default.
- W2811184474 hasConcept C164622146 @default.
- W2811184474 hasConcept C187212893 @default.
- W2811184474 hasConcept C201903717 @default.
- W2811184474 hasConcept C205545832 @default.
- W2811184474 hasConcept C2778527826 @default.
- W2811184474 hasConcept C2908647359 @default.
- W2811184474 hasConcept C41895202 @default.
- W2811184474 hasConcept C71924100 @default.
- W2811184474 hasConcept C72563966 @default.
- W2811184474 hasConcept C99454951 @default.
- W2811184474 hasConceptScore W2811184474C121608353 @default.
- W2811184474 hasConceptScore W2811184474C126322002 @default.
- W2811184474 hasConceptScore W2811184474C138885662 @default.
- W2811184474 hasConceptScore W2811184474C144024400 @default.
- W2811184474 hasConceptScore W2811184474C149923435 @default.
- W2811184474 hasConceptScore W2811184474C164622146 @default.
- W2811184474 hasConceptScore W2811184474C187212893 @default.
- W2811184474 hasConceptScore W2811184474C201903717 @default.
- W2811184474 hasConceptScore W2811184474C205545832 @default.
- W2811184474 hasConceptScore W2811184474C2778527826 @default.
- W2811184474 hasConceptScore W2811184474C2908647359 @default.
- W2811184474 hasConceptScore W2811184474C41895202 @default.
- W2811184474 hasConceptScore W2811184474C71924100 @default.
- W2811184474 hasConceptScore W2811184474C72563966 @default.
- W2811184474 hasConceptScore W2811184474C99454951 @default.
- W2811184474 hasIssue "2" @default.
- W2811184474 hasLocation W28111844741 @default.
- W2811184474 hasLocation W28111844742 @default.
- W2811184474 hasLocation W28111844743 @default.
- W2811184474 hasLocation W28111844744 @default.